Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Letter from the Editor
There is no doubt that the side effect endpoints a pharma company has to evaluate when they bring a new drug to market have increased over the past 15 years. We often mention that if some of the older diabetes medications had to go through the rigorous studies required today, most of them would have never made it onto the pharmacy shelves.
Although these studies are looking for side effects they oftentimes reveal positive effects for our patients. Last week we had a feature on how GLP-1RAs show positive results for use in type 1 patients. Another of these classes of drugs that has borne extra fruit is the SGLT-2 inhibitors. They were first approved for glucose control, but when further data was analyzed we found they helped with hypertension, kidney failure, and weight loss. This week our intern, Adrian Gavre, PharmD Candidate, Philadelphia College of Osteopathic Medicine, discusses the relationship of SGLT-2 inhibitors and anemia in renally challenged patients with diabetes. Take a look here at our Laterpay feature to learn what else these “diabetes” drugs can do.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
Newsflash: FDA OKs dasiglucagon pen for hypoglycemia treatment
The FDA has approved Zealand Pharma’s Zegalogue injection 0.6 mg as a treatment for patients aged 6 and above with severe hypoglycemia. Three trials involving diabetes patients who used the dasiglucagon injection showed they attained blood glucose recovery from severe hypoglycemia with a median time of 10 minutes. See news release.
TOP STORIES — Diabetes News and Research
SGLT-2 inhibitors show additional benefits besides lowering blood glucose.
Can an increase in waist circumference determine cardiovascular risk, separate from weight loss or gain?
Study of the Danish national register suggests that family members’ age at onset of diabetes could be an essential factor that is overlooked in determining type 2 risk.
Did You Know? Eating Before 8:30AM Reduces Risk Factors for Type 2 Diabetes:
According to a study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting, people who start eating before 8:30 a.m. had lower blood sugar levels and less insulin resistance, which could reduce the risk of developing type 2 diabetes, regardless of whether they restricted their food intake to less than 10 hours a day or their food intake was spread over more than 13 hours daily.
Previous studies have found that time-restricted eating, which consolidates eating to a shortened timeframe each day, has demonstrated improvement in metabolic health; researchers wanted to assess whether eating earlier in the day affected metabolic measures.
The researchers analyzed data from 10,575 adults who participated in the National Health and Nutrition Examination Survey. They divided participants into three groups depending on the total food intake duration: less than 10 hours, 10-13 hours, and more than 13 hours per day. They then created six subgroups based on eating duration start time (before or after 8:30 a.m.).
They analyzed this data to determine if eating duration and timing were associated with fasting blood sugar levels and estimated insulin resistance. Fasting blood sugar levels did not differ significantly among eating interval groups. Insulin resistance was higher with shorter eating interval duration but lower across all groups with an eating start time before 8:30 a.m.
These findings suggest that timing is more strongly associated with metabolic measures than duration and support early eating strategies.
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:
Alexandria Bartley, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences
Alexis Dunn, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences
Adrian Gavre, PharmD Candidate, Philadelphia College of Osteopathic Medicine
George McConnell, PharmD. Candidate, LECOM School of Pharmacy
Shadrielle Robbins, PharmD Candidate, South College School of Pharmacy
Mit Suthar, PharmD. Candidate, LECOM School of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com